UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 8, 2003
NPS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 0-23272 | 87-0439579 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
420 Chipeta Way
Salt Lake City, Utah 84108
(Address of Principal Executive Offices)
(801) 583-4939
(Registrant’s Telephone Number, Including Area Code)
ITEM 5: | Other Events |
On September 8, 2003, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
On September 20, 2003, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.2 and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 25, 2003 | NPS PHARMACEUTICALS, INC. | |||||||
By: | /s/ HUNTER JACKSON | |||||||
Hunter Jackson CEO, President and Chairman of the Board |
EXHIBIT INDEX
Exhibit Number | Description | |
99.1 | Press Release issued by NPS Pharmaceuticals, Inc. on September 8, 2003 announcing the NDA filing by Amgen Inc. for Cinacalcet HCl. | |
99.2 | Press Release issued by NPS Pharmaceuticals, Inc. on September 20, 2003 commenting on interim results of PaTh Study Data. |